Dr Hanny Al-Samkari speaks to ecancer about the evolving treatment landscape in immune thrombocytopenia, highlighting emerging therapeutic targets that may reshape clinical practice over the next decade.

He notes that novel agents are showing promise in improving efficacy, safety, and potentially offering more durable disease control compared with traditional approaches.

Dr Al-Samkari focuses on shifting first line management strategies, particularly the earlier use of thrombopoietin receptor agonists.

Clinicians are increasingly considering patient specific factors such as disease severity, bleeding risk, comorbidities, and treatment goals when deciding whether to introduce these agents earlier rather than reserving them for later lines.

In the oncology setting, the management of chemotherapy induced thrombocytopenia remains a critical challenge.

Current best practices emphasise individualised supportive care, with emerging therapies aiming to reduce treatment delays and maintain dose intensity across different cancer types and regimens.

Dr Al-Samkari highlights that we can see a move towards more personalised, proactive treatment strategies in both immune thrombocytopenia and chemotherapy related thrombocytopenia, with ongoing innovation expected to further improve patient outcomes.